share_log

Leerink Partners Upgrades AN2 Therapeutics to Outperform

Leerink Partners Upgrades AN2 Therapeutics to Outperform

Leerink Partners将AN2 Therapeutics升级为跑赢大盘
Benzinga ·  07/03 14:21

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.

Leerink Partners的分析师Joseph Schwartz将AN2 Therapeutics(纳斯达克:ANTX)的评级从Market Perform升级为Outperform。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发